John Sterling on Muck Rack

John Sterling

Verified
New York
As seen in: Genetic Engineering & Biotechnology News, SAGE Publishing, Touching Base (Genetic Engineering & Biotechnology News (GEN), Flipboard, The Salt Lake Tribune, Audubon, IndieBound, Inbound Logistics, Inside Precision Medicine
Editor in Chief of Genetic Engineering & Biotechnology News (GEN) since 1985; BS degree in biology from CCNY and MA in journalism from Univ of Minnesota
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John

Contact John, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering

|
By John Sterling Verified
| Genetic Engineering & Biotechnology News Verified
VectorBuilder and MaxCyte formed a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder’s MiniVec™ plasmid system and MaxCyte’s clinical electroporation platform for ex vivo cell engineering. Officials at both companies say that ex vivo cell therapies such as CAR-T, CAR-NK, and iPSC-based treatments have gained significant traction, but critical challenges in safety and manufacturability continue to limit their broader application.
Open in Who Shared View Duplicates (15) Issue with article?

IDBS and Alchemi Agree to Accelerate AI-Driven Biopharma Regulatory Filings

|
By John Sterling Verified
| Genetic Engineering & Biotechnology News Verified
Home Insights IDBS and Alchemi Agree to Accelerate AI-Driven Biopharma Regulatory Filings Credit: Rudall30/Getty Images IDBS, which provides cloud software for biopharma, and Alchemi, an applied AI company, partnered to connect AI agents to data captured and contextualized in the IDBS Polar platform across the drug development lifecycle.
Open in Who Shared View Duplicates (2) Issue with article?

Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech

|
By John Sterling Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Bioprocessing Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech Credit: Christoph Burgstedt/Science Photo Library/Getty Images Nirrin Technologies appointed S.T. Japan as its exclusive distribution partner for the TALOSTM protein quantitation system in Japan.
Open in Who Shared View Duplicates (2) Issue with article?
See all 2,766 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified